Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ORTHO-NOVUM 7/7/7-28 vs ALYACEN 7/7/7
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Combination of estrogen (ethinyl estradiol) and progestin (norethindrone) inhibits gonadotropin secretion, preventing ovulation; increases cervical mucus viscosity, impeding sperm penetration; alters endometrial development, reducing implantation likelihood.
Combination of norethindrone (progestin) and ethinyl estradiol (estrogen) that inhibits gonadotropin release from the pituitary, suppressing ovulation, increasing cervical mucus viscosity, and altering endometrial receptivity.
Prevention of pregnancy
Prevention of pregnancy
One tablet orally once daily for 28 consecutive days (21 active tablets followed by 7 placebo tablets). Each active tablet contains 0.035 mg ethinyl estradiol and varying progestin doses: 7 tablets of 0.5 mg norethindrone, 7 tablets of 0.75 mg norethindrone, and 7 tablets of 1 mg norethindrone.
ALYACEN 7/7/7 is a combination oral contraceptive containing ethinyl estradiol 0.02 mg and drospirenone 3 mg. One tablet taken orally once daily for 28 days (7 active, 7 placebo, 7 active) without a hormone-free interval.
EE: terminal half-life 13-27 hours (mean ~17 hours); NET: 7-13 hours (mean ~10 hours). Clinical context: steady state reached after 4-7 days; missed pills may reduce contraceptive efficacy.
Terminal elimination half-life is 14 hours (range 12-16 h) in healthy adults; prolonged to 24-30 h in moderate renal impairment (Cr Cl 30-50 m L/min).
Ethinyl estradiol and norethindrone undergo hepatic metabolism via CYP3A4 and other CYP450 enzymes. Conjugation and sulfation also occur.
Norethindrone: primarily hepatic via reduction and conjugation, with CYP3A4 involvement. Ethinyl estradiol: primarily via CYP3A4, also undergoes sulfation and glucuronidation.
Ethinyl estradiol (EE) is excreted in urine (40%) and feces (60%) as glucuronide and sulfate conjugates. Norethindrone (NET) is excreted primarily in urine (60-80%) as glucuronide conjugates, with 10% in feces. Biliary excretion contributes minimally.
Renal: ~50% (unchanged drug); Fecal: ~20% (via bile); Biliary: ~30% (metabolites). Total clearance is 12 L/h.
EE: 98% bound to albumin; induces SHBG synthesis, increasing binding capacity. NET: 61% bound to albumin, 36% bound to SHBG.
98% bound primarily to albumin; minor binding to alpha-1-acid glycoprotein.
EE: 2.5-5.0 L/kg (mean 4 L/kg); large Vd due to extensive tissue distribution. NET: 1.5-4.0 L/kg (mean 2.5 L/kg); distributes into breast milk.
0.35 L/kg (total body water distribution); in obesity, Vd increases to 0.5 L/kg due to lipophilicity.
EE: 38-48% due to first-pass metabolism (sulfation in gut wall and 2-hydroxylation in liver). NET: 50-77% (mean 64%) with high first-pass metabolism.
Oral: 85% (with high-fat meal reduces to 70%); Sublingual: 90%.
No specific dosage adjustments recommended for renal impairment. Use with caution in severe renal impairment due to potential for fluid retention and hypertension.
Contraindicated in patients with severe renal impairment (Cr Cl <30 m L/min) or acute renal failure due to drospirenone's antimineralocorticoid activity. No dose adjustment recommended for mild to moderate impairment (Cr Cl ≥30 m L/min).
Contraindicated in acute hepatitis, severe cirrhosis, or liver tumors. For mild hepatic impairment (Child-Pugh A), use with caution; no specific dose adjustment established. Not recommended in moderate to severe impairment (Child-Pugh B or C) due to reduced metabolism of steroid hormones.
Contraindicated in patients with acute hepatic disease, hepatic tumors, or impaired liver function (Child-Pugh class B or C). Discontinue if jaundice or pruritus develops. No dose adjustment for Child-Pugh class A.
Not indicated for premenarchal girls. For postmenarchal adolescents, dosage is the same as adults (one tablet daily) but initiation should be based on clinical judgment and individual risk factors.
Not indicated for use in pediatric patients before menarche. Safety and efficacy in postmenarchal adolescents are expected to be similar to adults; dose is same as adults.
Not indicated for postmenopausal women. No specific dosing recommendations; use not appropriate in this age group due to lack of contraceptive need and potential increased risk of vascular events.
Not indicated for use in postmenopausal women. No recommendations for geriatric population due to lack of indication.
Cigarette smoking increases risk of serious cardiovascular events from combination oral contraceptive use. Risk increases with age and heavy smoking (>15 cigarettes/day). Women over 35 who smoke should not use this product.
Cigarette smoking increases risk of serious cardiovascular events from combined oral contraceptives (COCs). Risk increases with age and amount smoked (especially >15 cigarettes/day). Women over 35 who smoke should not use COCs.
Increased risk of thromboembolic disorders; use caution in patients with cardiovascular risk factors. Monitor blood pressure. Discontinue if jaundice, visual disturbances, or migraine occurs. May affect glucose tolerance. Use with caution in patients with history of depression.
Thrombotic disorders (thrombophlebitis, pulmonary embolism, cerebral hemorrhage, myocardial infarction),Cerebrovascular disease,Carcinoma of the breast or reproductive organs,Hepatic adenoma or carcinoma,Ocular lesions (retinal thrombosis, papilledema),Gallbladder disease,Carbohydrate/lipid effects,Elevated blood pressure,Hereditary angioedema,Chloasma,Hepatic impairment
Thrombophlebitis or thromboembolic disorders; history of deep vein thrombosis or pulmonary embolism; cerebrovascular or coronary artery disease; known or suspected breast cancer; endometrial cancer or other estrogen-dependent neoplasia; undiagnosed abnormal genital bleeding; cholestatic jaundice of pregnancy or jaundice with prior pill use; hepatic adenoma or carcinoma; known or suspected pregnancy; hypersensitivity to any component; cigarette smoking in women over age 35.
Breast cancer (current or history),Undiagnosed abnormal genital bleeding,Known or suspected pregnancy,Current or history of thrombotic disorders (DVT, PE, stroke, MI),Cerebrovascular or coronary artery disease,Valvular heart disease with complications,Severe hypertension,Diabetes with vascular disease,Headaches with focal neurological symptoms (e.g., migraine with aura),Major surgery with prolonged immobilization,Known thrombophilia (e.g., Factor V Leiden, prothrombin mutation, protein S/C deficiency),Active liver disease (tumors, hepatitis, cirrhosis),Uncontrolled hypertension,Smoking (if age >35),Hypersensitivity to any component
No specific food restrictions; grapefruit juice may increase ethinyl estradiol levels and should be avoided or minimized. High-fat meals may slightly increase absorption but not clinically significant.
Grapefruit and grapefruit juice may increase ethinyl estradiol levels, potentially increasing side effects. St. John's wort (herbal supplement) can reduce contraceptive efficacy. No other significant food interactions; however, maintaining a stable intake of vitamin C and folate is generally recommended.
Combined hormonal contraceptives (CHCs) including ORTHO-NOVUM 7/7/7-28 are contraindicated during pregnancy. First trimester exposure: no consistent evidence of major malformations (e.g., VACTERL) from epidemiologic studies, but a small increased risk of cardiovascular defects and limb reduction defects cannot be excluded. Second and third trimester exposure: risk of maternal and fetal adverse outcomes, including fetal growth restriction, preterm delivery, and potential masculinization of female fetuses from progestins. Use is contraindicated once pregnancy is suspected or confirmed.
ALYACEN 7/7/7 contains ethinylestradiol and norethindrone. First trimester: No increased risk of major birth defects based on epidemiologic studies; however, inadvertent use does not warrant termination. Second and third trimesters: Avoid use due to potential adverse effects on fetal development, including feminization of male fetuses and potential for congenital anomalies from progestin. Postnatal: Possible long-term effects on reproductive development.
CHCs like ORTHO-NOVUM 7/7/7-28 may reduce milk production and quality, especially in early postpartum. Small amounts of ethinyl estradiol and norethindrone are excreted into breast milk; estimated infant dose is <1% of maternal weight-adjusted dose. Milk-to-plasma (M/P) ratio for norethindrone is approximately 0.1–0.5; ethinyl estradiol M/P ratio is not well defined. Use during lactation is generally not recommended; progestin-only contraceptives are preferred. If used, initiate after established breastfeeding (≥6 months).
Contraindicated in breastfeeding. Ethinylestradiol reduces milk quantity and quality. Norethindrone is excreted in low amounts (M/P ratio approximately 0.3-0.4). However, combination oral contraceptives are not recommended during lactation due to estrogen effects on milk production.
ORTHO-NOVUM 7/7/7-28 is contraindicated during pregnancy. No dose adjustments are applicable as use is not recommended. Pharmacokinetic changes in pregnancy (increased clearance, volume of distribution) are not relevant due to contraindication.
ALYACEN 7/7/7 is contraindicated in pregnancy; no dose adjustments are applicable as use is not recommended. Pharmacokinetic changes in pregnancy (increased clearance of steroids) would theoretically require higher doses, but due to fetal risks, alternative therapies should be used.
Fixed-dose combination of norethindrone and ethinyl estradiol; pill sequence has 7 white (0.5mg norethindrone/35mcg EE), 7 light peach (0.75mg/35mcg), 7 peach (1mg/35mcg), 7 green (placebo). Missed pills increase breakthrough bleeding risk; if one pill missed, take as soon as remembered; if two or more, use backup contraception for 7 days. Consider progestin-only alternatives in patients with migraine with aura, uncontrolled hypertension, or smoking >35. Potential for reduced efficacy with enzyme-inducing antiepileptics (e.g., carbamazepine) and rifampin. Increased VTE risk, especially in first year of use. Estrogen-containing contraceptives can increase hepatic clearance of some drugs. Not suitable for breastfeeding within first 6 weeks postpartum due to estrogen effect on milk supply.
ALYACEN 7/7/7 is a triphasic oral contraceptive containing ethinyl estradiol and norgestimate. The 7/7/7 regimen refers to the varying doses of norgestimate across three 7-day phases (0.18 mg, 0.215 mg, 0.25 mg) with a fixed 0.025 mg ethinyl estradiol. Use consistent 7-day placebo interval. Consider increased risk of venous thromboembolism (VTE) in patients with BMI >30, smoking >15 cigarettes/day, or age >35. Monitor for breakthrough bleeding, especially during the first 3 cycles. Avoid in patients with migraine with aura, uncontrolled hypertension, or history of DVT/PE. Drug interactions with CYP3A4 inducers (e.g., rifampin, carbamazepine) may reduce efficacy; consider backup contraception.
Take one pill daily at the same time; start on first day of menstrual period or first Sunday after period begins (check package instructions).,The pill pack has 3 different colored active pills (white, light peach, peach) with increasing progestin dose, followed by 7 green placebo pills; continue taking daily even during placebo week.,If you miss one active pill, take it as soon as remembered and take next pill at usual time (may take 2 pills in one day).,If two or more active pills are missed, take the last missed pill now, discard others, continue with remaining pills; use backup contraception (e.g., condoms) for next 7 days.,Common side effects: nausea, breast tenderness, spotting (especially in first few months); report leg swelling, chest pain, severe headache, or vision changes.,Avoid grapefruit juice as it may increase estrogen levels; no known food restrictions otherwise.,Smoking increases risk of serious cardiovascular events; advise smoking cessation.,Do not use while pregnant; if pregnancy suspected, discontinue and consult healthcare provider.
Take one pill daily at the same time each day, in the order specified on the pack (active pills followed by placebo).,If you miss a pill, follow the package instructions; missing pills increases pregnancy risk, especially if placebo week is extended.,Common side effects include nausea, headache, breast tenderness, and spotting, which usually improve after 2-3 cycles.,Seek immediate medical attention for severe abdominal pain, chest pain, shortness of breath, leg pain/swelling, or severe headache.,This medication does not protect against HIV/AIDS or other sexually transmitted infections (STIs).,Inform your healthcare provider if you smoke, as smoking increases risk of serious cardiovascular side effects, especially if over 35 years.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ORTHO-NOVUM 7/7/7-28 vs ALYACEN 7/7/7, answered by our medical review team.
ORTHO-NOVUM 7/7/7-28 is a Oral Contraceptive that works by Combination of estrogen (ethinyl estradiol) and progestin (norethindrone) inhibits gonadotropin secretion, preventing ovulation; increases cervical mucus viscosity, impeding sperm penetration; alters endometrial development, reducing implantation likelihood.. ALYACEN 7/7/7 is a Oral Contraceptive that works by Combination of norethindrone (progestin) and ethinyl estradiol (estrogen) that inhibits gonadotropin release from the pituitary, suppressing ovulation, increasing cervical mucus viscosity, and altering endometrial receptivity.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ORTHO-NOVUM 7/7/7-28 and ALYACEN 7/7/7 depend on the specific clinical indication. These are both Oral Contraceptive agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ORTHO-NOVUM 7/7/7-28 is: One tablet orally once daily for 28 consecutive days (21 active tablets followed by 7 placebo tablets). Each active tablet contains 0.035 mg ethinyl estradiol and varying progestin doses: 7 tablets of 0.5 mg norethindrone, 7 tablets of 0.75 mg norethindrone, and 7 tablets of 1 mg norethindrone.. The standard adult dose of ALYACEN 7/7/7 is: ALYACEN 7/7/7 is a combination oral contraceptive containing ethinyl estradiol 0.02 mg and drospirenone 3 mg. One tablet taken orally once daily for 28 days (7 active, 7 placebo, 7 active) without a hormone-free interval.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ORTHO-NOVUM 7/7/7-28 and ALYACEN 7/7/7 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ORTHO-NOVUM 7/7/7-28 is classified as Category C. Combined hormonal contraceptives (CHCs) including ORTHO-NOVUM 7/7/7-28 are contraindicated during pregnancy. First trimester exposure: no consistent evidence of major malformations. ALYACEN 7/7/7 is classified as Category C. ALYACEN 7/7/7 contains ethinylestradiol and norethindrone. First trimester: No increased risk of major birth defects based on epidemiologic studies; however, inadvertent use does n. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.